China Expands GSP To Clarify Drug Distribution Roles
This article was originally published in PharmAsia News
Executive Summary
China’s Ministry of Health recently released a draft GSP to expand the rule from 88 articles to 201 articles; public comments close May 27.
You may also be interested in...
China's Top Drug Distributors Are Soaring: China Earnings Round Up (Part 2)
SHANGHAI - China's drug distribution market and retail pharmacy revenue reached RMB 708 billion ($110.9 billion) in 2010, a 24.6% increase from 2009, and the top three drug distributors' market share increased by 5.8% to 26.7% through aggressive acquisitions to expand their distribution networks, according to China's Ministry of Commerce.
Cardinal Health's Acquisition Of Zuellig Pharma Signal Of China's Intent To Allow More Foreign Investment?
SHANGHAI - In what some are calling a transformational event for the China pharma industry, Cardinal Health announced Nov. 29 that it has closed a deal to acquire local private distributor Zuellig Pharma China (Yong Yu in Chinese) for $470 million
CROs at risk from China's new inventor regulation?
China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.